DOCSLIB.ORG

Jeffrey D. Wayne, MD Curriculum Vitae California License #G65909 DEA License #BW1848211 Principal Investigator - Owner | Clinical Trials Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jeffrey D. Wayne, MD Curriculum Vitae California License #G65909 DEA License #BW1848211 Principal Investigator - Owner | Clinical Trials Research Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR Jeffrey D. Wayne, MD Curriculum Vitae California License #G65909 DEA License #BW1848211 Principal Investigator - Owner | Clinical Trials Research Clinical Trials Research Investigators 160 Gateway Drive, Suite 100 Joseph D. Hobbs, PA-C Lincoln, CA 95648 Robyn Lawrie, NP (916) 434-8230 Phone Sharmila Chatterjee, MD, MPH (916) 434-8237 Fax H. Douglas Cooper, MD (Ophthalmology) 3750 Auburn Boulevard, Suite A Research Coordinators Sacramento, CA 95821 (916) 434-8230 Phone Leesa Koskela, CCRC (Clinical Director) (916) 487-8237 Fax Tammy Ward, CRC Marissa Tangerini, BS, CCRC Stacey Adams, CRC Kari Sue Jones, CCRC Kadijah Washington, CRC Education 1978-1982 University of Southern California Keck School of Medicine – MD Degree 1974-1978 Emory University Atlanta, GA – BA Psychology Professional Experience 1999-Present Clinical Trials Research, Owner/Principal Investigator 1992-Present Clinical Trials, Principal Investigator 1989-Present Internal Medicine (Private Practice), Owner 1 | P a g e Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR 2006-2007 Howe Medical Clinic, Medical Director 1997-1999 Sacramento Health and Weight Management, Inc, Medical Director 1986-1989 Faulkner Hospital, ER Attending Physician, Clinical Instructor Professional Training 1983-1986 Residency – Internal Medicine – Faulkner Hospital Tufts University School of Medicine, Boston, Mass Board Certified in Internal Medicine - 1987 1982-1983 Internship – Family Practice – University of Southern California Presbyterian Intercommunity Hospital Family Medicine Program at Los Angeles County Hospital Clinical Research Experience 28 years conducting clinical trials as Principal Investigator in multiple therapeutic areas including but not limited to hypertension, diabetes, cardiovascular, respiratory, women’s health, men’s health. Approximately 260 trials completed. Academic Appointments and Memberships Present Appointment 2014-Present Volunteer Clinical Faculty, University of California, Davis School of Medicine Previous Appointments 1999-2016 Office based staff member, Mercy San Juan Hospital 1999-2008 Senior staff member, Sutter Roseville Medical Center 1992-2005 Qualified Medical Examiner, State of California, Industrial Medical Council 2 | P a g e Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR 1999-2008 Medical Director, Eskaton Home Care 1996-1997 Clinical Preceptor, University of San Francisco School of Nursing, Nurse Practitioner Program 1992-1994 Director of Clinical Research, Sutter Medical Group 1991-1993 Clinical Preceptor, University of California, Davis, Medical Center Physician Assistant Program 1989-1999 Senior Staff Member, Mercy American River Hospital and Mercy San Juan Hospital 1986-1989 Clinical Instructor, Tufts University School of Medicine Clinical Trials TAP Pharmaceuticals Generalized Anxiety Disorder Study. Double-Blind, Fixed Dose Multicenter Study Comparing XXXX to XXXX and Placebo in Patients with Generalized Anxiety Disorder. Merck Sharpe and Dohme Ace Inhibitor Cough Study. A Multicenter, Double-Blind, Randomized, Parallel Group Study to Investigate the Incidence of Cough in Patients Receiving XXXX or XXXX who have Reported Cough with an Angiotensin Converting Enzyme Inhibitor. Norwich-Eaton Urinary Tract Infection (UTI) Study. An Open Label, Multicenter Study to Compare the Safety and Efficacy of XXXX for Seven Days to XXXX for Ten Days in the Treatment of Acute, Uncomplicated Lower Urinary Tract Infections. Ciba-Geigy Corporation Hypertension Study. A Randomized, Doub1e-B1ind, Parallel Trial Comparing XXXX, XXXX, and XXXX in Patients Age 18-80 Years with Essential Hypertension Inadequately Controlled with XXXX Followed by a Single-Blind Extension of XXXX. 3 | P a g e Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR Medeva Hepatitis Study. A Multicenter, Randomized, Double-Blind Study in Normal, Healthy Subjects to evaluate the Efficacy and Safety of Two-Dose, One Month Regimen of XXXX Compared to XXXX and to a Three Dose, Two Month Regimen of XXXX. TAP Holdings Dyspepsia Study. A Study to Evaluate the Effects of XXXX 30 mg or 15 mg QD versus Placebo in Patients with Non-Ulcer Dyspepsia. Glaxo Wellcome Chronic Bronchitis Study. A Randomized, Double-Blind Multicenter Comparison of the Efficacy and Safety of XXXX 400 mg or 600 mg Once Daily and XXXX 500 mg Twice Daily in the Treatment of Patients with Acute Bacterial Exacerbations of Chronic Bronchitis. Novartis Pharmaceuticals Diabetes Study. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy, Tolerability and Safety of XXXX Monotherapy, XXXX Monotherapy and a Combination of XXXX and XXXX to Placebo in Subjects with Non- Insulin Dependent Diabetes Mellitus Inadequately Controlled on Diet Alone. TAP Holdings GERD Study. Study to Evaluate the Effects of XXXX 5 mg QID, 10 mg TID, 20 mg BID Versus Placebo in Females with Non-Erosive Gastroesophageal Reflux Disease. Kos Pharmaceuticals Lipid Study. A Long-Term, Open-Label, Multicenter Trial of the Safety and Efficacy of Nicostatin in Patients with Dyslipidemia. Medeva Hepatitis Study. A Multicenter, Long-Term, Follow-up Study of the Duration of Seroprotection After XXXX, and an Open-Label Study of the Efficacy and Safety of a Single Dose of XXXX in Subjects with Low XXXX Values. Berlex Laboratories Menopause Study. A Multicenter, Double-Blind, Randomized Study of Continuous XXXX Combinations, Compared to Continuous XXXX, to Examine the Safety and Effect on the Endometrium, Symptoms and Bleeding Patterns in Postmenopausal Women. 4 | P a g e Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR Merck & Co. Osteoarthritis Study. A Randomized, Double Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of XXXX 25 mg qd vs XXXX 500 mg bid. in Patients with Osteoarthritis. Novartis Pharmaceuticals Diabetes Study. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Dose Levels of Nateglinide and Placebo in Type 2 Diabetes Mellitus patients with Minimally Elevated Fasting Plasma Glucose Levels. TAP Pharmaceuticals Irritable Bowel Syndrome (IBS) Study. A Study to Evaluate the Safety and Efficacy of XXXX (30 mg BID, 60 mg BID and 120 mg BID) vs XXXX in Subjects with Irritable Bowel Syndrome. Novartis Pharmaceuticals Functional Dyspepsia and Delayed Gastric Emptying Study. A Randomized, Double- Blind, Placebo-Controlled, Dose Finding, Multicenter Study to Assess, the Efficacy, Safety and Tolerability of XXXX Given Orally at Three Dose Levels (1 mg, 4 mg or 12 mg), and XXXX in Patients with Functional Dyspepsia (FD) and Documented Normal Gastric Emptying. Novartis Pharmaceuticals Functional Dyspepsia and Delayed Gastric Emptying Study. A Randomized, Double- Blind, Placebo-Controlled, Dose Finding, Multicenter Study to Assess the Efficacy, Safety and Tolerability of XXXX Given Orally at Three Dose Levels (4mg, 12 mg or 24 mg) and XXXX in Patients with Functional Dyspepsia (FD) and Documented Delayed Gastric Emptying. Takeda Pharmaceuticals North America Diabetes / CHF Study. A Randomized, Double-Blind, Comparator-Controlled Study of XXXX vs XXXX in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure. Takeda Pharmaceuticals North America Diabetes / Cardiovascular Study. A Randomized, Double-Blind, Comparator-Controlled Study of XXXX vs. XXXX in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I). 5 | P a g e Jeffrey D. Wayne, MD Clinical Trials Research, Inc PRINCIPAL INVESTIGATOR Bertek Pharmaceuticals Hypertension Study. A Double-Blind, Multicenter, randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of XXX Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension. Eli Lilly Diabetic Peripheral Neuropathy Study. LY333531 Treatment of Peripheral Neuropathy in Patients with Diabetes. Bristol-Myers Squibb Diabetes Study. A Randomized, Double-Blind, Dose Ranging, Dose Comparison- Controlled Trial to Determine the Safety and Efficacy of XXXX in Patients with Type 2 Diabetes Solvay Pharmaceuticals Irritable Bowel Syndrome Study. A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of Cilansetron over 12 Weeks Followed by a 4-week XXX Treatment Period in Diarrhea-Predominant Irritable Bowel Syndrome Subjects. Novartis Pharmaceuticals African American Hypertension Study. A Double-Blind, Randomized, Parallel Group Study Comparing the Effects of XXX to XXX in African American Patients with Mild to Moderate Hypertension. Novartis Pharmaceuticals Impaired Glucose Tolerance (IGT) Study. A Multinational, Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, 2 X 2 Factorial Design Study of the Efficacy and Safety of Long Term Administration of XXX and XXXX in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects with Impaired Glucose Tolerance (IGT). Novartis Pharmaceuticals Hypertension Study. A Multicenter Prospective, Randomized, Open-Label, Blinded End-Point, Parallel Group Study Comparing the Effects of XXX(5/20mg) to XXXX (5 mg) and XXXX (20 mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension. Takeda Pharmaceuticals North America Congestive Heart
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,486,621 B2 Luo Et Al
    USOO8486.621B2 (12) United States Patent (10) Patent No.: US 8,486,621 B2 Luo et al. (45) Date of Patent: Jul. 16, 2013 (54) NUCLEICACID-BASED MATRIXES 2005. O130180 A1 6/2005 Luo et al. 2006/0084607 A1 4/2006 Spirio et al. (75) Inventors: ity, N. (US); Soong Ho 2007/01482462007/0048759 A1 3/20076/2007 Luo et al. m, Ithaca, NY (US) 2008.0167454 A1 7, 2008 Luo et al. 2010, O136614 A1 6, 2010 Luo et al. (73) Assignee: Cornell Research Foundation, Inc., 2012/0022244 A1 1, 2012 Yin Ithaca, NY (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/057023 A1 T 2004 patent is extended or adjusted under 35 U.S.C. 154(b) by 808 days. OTHER PUBLICATIONS Lin et al. (J Biomech Eng. Feb. 2004;126(1):104-10).* (21) Appl. No.: 11/464,184 Li et al. (Nat Mater. Jan. 2004:3(1):38-42. Epub Dec. 21, 2003).* Ma et al. (Nucleic Acids Res. Dec. 22, 1986;14(24):9745-53).* (22) Filed: Aug. 11, 2006 Matsuura, et al. Nucleo-nanocages: designed ternary oligodeoxyribonucleotides spontaneously form nanosized DNA (65) Prior Publication Data cages. Chem Commun (Camb). 2003; (3):376-7. Li, et al. Multiplexed detection of pathogen DNA with DNA-based US 2007/01 17177 A1 May 24, 2007 fluorescence nanobarcodes. Nat Biotechnol. 2005; 23(7): 885-9. Lund, et al. Self-assembling a molecular pegboard. JAm ChemSoc. Related U.S. Application Data 2005; 127(50): 17606-7. (60) Provisional application No. 60/722,032, filed on Sep.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives
    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome
    Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2012, Article ID 486067, 11 pages doi:10.1155/2012/486067 Review Article Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome Emanuele Sinagra, Claudia Romano, and Mario Cottone Division of Internal Medicine “Villa Sofia-V. Cervello” Hospital, University of Palermo, Via Trabucco 180, 90146 Palermo, Italy Correspondence should be addressed to Emanuele Sinagra, [email protected] Received 20 March 2012; Revised 28 May 2012; Accepted 4 July 2012 Academic Editor: Giovanni Barbara Copyright © 2012 Emanuele Sinagra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Irritable bowel syndrome (IBS) accounts for 25% of gastroenterology output practice, making it one of the most common disorders in this practice. Psychological and social factors may affect the development of this chronic disorder. Furthermore, psychiatric symptoms and psychiatric diseases are highly prevalent in this condition, but the approach to treating these is not always straightforward. As emphasized in the biopsychosocial model of IBS, with regard to the modulatory role of stress-related brain-gut interactions and association of the disease with psychological factors and emotional state, it proves useful to encourage psychopharmacological treatments and psychosocial therapies, both aiming at reducing stress perception. The aim of this paper is to analyze the effectiveness of psychopharmacological treatment and psychological interventions on irritable bowel syndrome. 1. Introduction In fact, IBS has a multifactorial etiology, involving altered gut reactivity and motility, altered pain perception, and Irritable bowel syndrome (IBS) is a chronic, relapsing, and alteration of the brain-gut axis [8].
    [Show full text]
  • Impact of Mirabegron Extended-Release on the Treatment of Overactive Bladder with Urge Urinary Incontinence, Urgency, and Frequency
    University of Massachusetts Medical School eScholarship@UMMS University of Massachusetts Medical School Faculty Publications 2013-10-25 Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency Raymond Lee University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Male Urogenital Diseases Commons, and the Urology Commons Repository Citation Lee R, Bamberger MH, Ellsworth P. (2013). Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.2147/RRU.S38792. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/771 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Research and Reports in Urology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency Raymond T Lee1 Abstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality Mitchell Bamberger2 of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory Pamela Ellsworth3 efficacy and/or tolerability.
    [Show full text]
  • Pharmacological Treatment of Urinary Incontinence
    Committee 8 Pharmacological Treatment of Urinary Incontinence Chairman KARL-ERIK ANDERSSON (USA) Co-Chairman C. R CHAPPLE (U.K) Members L. CARDOZO (U.K), F. C RUZ (Portugal), H. HASHIM (U.K), M.C. MICHEL (The Netherlands), C. TANNENBAUM (Canada), A.J. WEIN (USA) 631 CONTENTS A. INTRODUCTION X. OTHER DRUGS I. PUBLICATION SEARCHES XI. COMBINATIONS II. CENTRAL NERVOUS CONTROL XII. FUTURE POSSIBILITIES III.PERIPHERALNERVOUS CONTROL C.DRUGS USED FOR IV. PATHOGENESIS OF BLADDER TREATMENT OF STRESS CONTROL DISORDERS URINARY INCONTINENCE V. BLADDER CONTRACTION I. α-ADRENCEPTOR AGONISTS VI. MUSCARINIC RECEPTORS II. β-ADRENOCEPTOR ANTAGONISTS B. DRUGS USED FOR TREATMENT OF OVERACTIVE III. β-ADRENOCEPTOR AGONISTS BLADDER SYMPTOMS/ DETRUSOR OVERACTIVITY IV. SEROTONIN-NORADRENALINE UPTAKE INHIBITORS I. ANTIMUSCARINIC (ANTICHOLINERGIC) DRUGS D.DRUGS USED FOR II. DRUGS ACTING ON MEMBRANE TREATMENT OF CHANNELS OVERFLOW INCONTINENCE III. DRUGS WITH “MIXED” ACTION E. HORMONALTREATMENT OF URINARY INCONTINENCE IV. α-ADRENOCEPTOR (AR) ANTAGONISTS I. ESTROGENS V. β-ADRENOCEPTOR AGONISTS II. OTHER STEROID HORMONE VI. PHOSPHODIESTERASE (PDE) RECEPTOR LIGANDS INHIBITORS III. DESMOPRESSIN VII. ANTIDEPRESSANTS VIII. CYCLOOXYGENASE (COX) INHIBITORS F. CONSIDERATIONS IN THE ELDERLY IX. TOXINS REFERENCES 632 Pharmacological Treatment of Urinary Incontinence KARL-ERIK ANDERSSON C. R CHAPPLE, L. CARDOZO, F. CRUZ, H. HASHIM, M.C. MICHEL, C. TANNENBAUM, A.J. WEIN Table 1. ICI assessments 2008: Oxford guidelines (modified) A. INTRODUCTION Levels of evidence Level 1: Systematic reviews, meta-analyses, good The function of the lower urinary tract (LUT) is to store quality randomized controlled clinical trials and periodically release urine, and is dependent on (RCTs) the activity of smooth and striated muscles in the Level 2: RCTs , good quality prospective cohort bladder, urethra, and pelvic floor.
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]